RxDoctor Payments Data

Kevin Jones, DO

Family Medicine · Tulsa, OKNPI 1215467055

Payments from drug & device makers

$12,752in general payments, 2019–2025

Across 772 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • GSK$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • plus $5K from 32 others

What the payments were for

  • Food & beverage$12,694100%
  • Education$570%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,752 in reported general payments places this provider in the 95th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$86,144
Medicare patients
152
Services billed
2,050

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide132$188,625
JardianceEmpagliflozin120$130,175
FarxigaDapagliflozin Propanediol91$105,552
EliquisApixaban99$96,750
MounjaroTirzepatide71$84,832
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$70,402
JanuviaSitagliptin Phosphate36$45,091
TrulicityDulaglutide23$42,651
KerendiaFinerenone12$22,040
UbrelvyUbrogepant12$20,926
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,901
Tresiba Flextouch U-100Insulin Degludec19$18,439
Xigduo XrDapaglifloz Propaned/Metformin17$17,685
Tresiba Flextouch U-200Insulin Degludec18$16,291
LinzessLinaclotide15$13,334

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$1,058$196,595146 claims
AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere$1,160$130,262127 claims
Boehringer IngelheimJardiance$309$130,175120 claims
Lilly USA, LLCMounjaro, Trulicity$1,106$127,48394 claims
PfizerEliquis$1,007$96,75099 claims
GSKTrelegy Ellipta$1,114$70,40298 claims
MerckJanuvia, Belsomra$210$51,72051 claims
AbbVieUbrelvy, Linzess$1,936$34,26027 claims
BayerKerendia$228$22,04012 claims
Sumitomo Pharma America, Inc.Gemtesa$90$12,21611 claims
NovartisEntresto$72$11,91814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →